These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 38855392)

  • 21. Clinical effectiveness and cost-effectiveness of physiotherapy and occupational therapy versus no therapy in mild to moderate Parkinson's disease: a large pragmatic randomised controlled trial (PD REHAB).
    Clarke CE; Patel S; Ives N; Rick CE; Woolley R; Wheatley K; Walker MF; Zhu S; Kandiyali R; Yao G; Sackley CM
    Health Technol Assess; 2016 Aug; 20(63):1-96. PubMed ID: 27580669
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biomarkers in Parkinson's disease: a funder's perspective.
    Frasier M; Chowdhury S; Eberling J; Sherer T
    Biomark Med; 2010 Oct; 4(5):723-9. PubMed ID: 20945984
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Harnessing digital technology to predict, diagnose, monitor, and develop treatments for brain disorders.
    Stroud C; Onnela JP; Manji H
    NPJ Digit Med; 2019; 2():44. PubMed ID: 31304390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of smartphone-based testing to generate exploratory outcome measures in a phase 1 Parkinson's disease clinical trial.
    Lipsmeier F; Taylor KI; Kilchenmann T; Wolf D; Scotland A; Schjodt-Eriksen J; Cheng WY; Fernandez-Garcia I; Siebourg-Polster J; Jin L; Soto J; Verselis L; Boess F; Koller M; Grundman M; Monsch AU; Postuma RB; Ghosh A; Kremer T; Czech C; Gossens C; Lindemann M
    Mov Disord; 2018 Aug; 33(8):1287-1297. PubMed ID: 29701258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interview with Mark Frasier: a Michael J Fox Foundation perspective on precision medicine in Parkinson's.
    Frasier MA
    Per Med; 2017 Jan; 14(1):13-15. PubMed ID: 29749821
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study.
    Nalls MA; McLean CY; Rick J; Eberly S; Hutten SJ; Gwinn K; Sutherland M; Martinez M; Heutink P; Williams NM; Hardy J; Gasser T; Brice A; Price TR; Nicolas A; Keller MF; Molony C; Gibbs JR; Chen-Plotkin A; Suh E; Letson C; Fiandaca MS; Mapstone M; Federoff HJ; Noyce AJ; Morris H; Van Deerlin VM; Weintraub D; Zabetian C; Hernandez DG; Lesage S; Mullins M; Conley ED; Northover CA; Frasier M; Marek K; Day-Williams AG; Stone DJ; Ioannidis JP; Singleton AB;
    Lancet Neurol; 2015 Oct; 14(10):1002-9. PubMed ID: 26271532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Design of a virtual longitudinal observational study in Parkinson's disease (AT-HOME PD).
    Schneider RB; Omberg L; Macklin EA; Daeschler M; Bataille L; Anthwal S; Myers TL; Baloga E; Duquette S; Snyder P; Amodeo K; Tarolli CG; Adams JL; Callahan KF; Gottesman J; Kopil CM; Lungu C; Ascherio A; Beck JC; Biglan K; Espay AJ; Tanner C; Oakes D; Shoulson I; Novak D; Kayson E; Ray Dorsey E; Mangravite L; Schwarzschild MA; Simuni T;
    Ann Clin Transl Neurol; 2021 Feb; 8(2):308-320. PubMed ID: 33350601
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improved measurement of disease progression in people living with early Parkinson's disease using digital health technologies.
    Czech MD; Badley D; Yang L; Shen J; Crouthamel M; Kangarloo T; Dorsey ER; Adams JL; Cosman JD
    Commun Med (Lond); 2024 Mar; 4(1):49. PubMed ID: 38491176
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Opportunities and challenges of entertainment-education: Learning about Parkinson's disease via The Michael J. Fox Show.
    Link E; Schluetz DM; Brauer S
    Commun Med; 2016; 13(2):203-214. PubMed ID: 29958362
    [TBL] [Abstract][Full Text] [Related]  

  • 31. DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.
    Trinh J; Gustavsson EK; Vilariño-Güell C; Bortnick S; Latourelle J; McKenzie MB; Tu CS; Nosova E; Khinda J; Milnerwood A; Lesage S; Brice A; Tazir M; Aasly JO; Parkkinen L; Haytural H; Foroud T; Myers RH; Sassi SB; Hentati E; Nabli F; Farhat E; Amouri R; Hentati F; Farrer MJ
    Lancet Neurol; 2016 Nov; 15(12):1248-1256. PubMed ID: 27692902
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of an online portal to facilitate clinical trial recruitment: a preliminary analysis of Fox Trial Finder.
    Rocker C; Cappelletti L; Marshall C; Meunier CC; Brooks DW; Sherer T; Chowdhury S
    J Parkinsons Dis; 2015; 5(1):55-66. PubMed ID: 25624422
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective.
    Stephenson D; Badawy R; Mathur S; Tome M; Rochester L
    J Parkinsons Dis; 2021; 11(s1):S103-S109. PubMed ID: 33579873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Innovative Recruitment Strategies to Increase Diversity of Participation in Parkinson's Disease Research: The Fox Insight Cohort Experience.
    Dobkin RD; Amondikar N; Kopil C; Caspell-Garcia C; Brown E; Chahine LM; Marras C; Dahodwala N; Mantri S; Standaert DG; Dean M; Shoulson I; Marek K; Katz A; Korell M; Riley L; Tanner CM;
    J Parkinsons Dis; 2020; 10(2):665-675. PubMed ID: 32250321
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Athauda D; Maclagan K; Skene SS; Bajwa-Joseph M; Letchford D; Chowdhury K; Hibbert S; Budnik N; Zampedri L; Dickson J; Li Y; Aviles-Olmos I; Warner TT; Limousin P; Lees AJ; Greig NH; Tebbs S; Foltynie T
    Lancet; 2017 Oct; 390(10103):1664-1675. PubMed ID: 28781108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Patient and Expert Perceptions of the Attainment of Research Milestones in Parkinson's Disease.
    Kane PB; Benjamin DM; Barker RA; Lang AE; Sherer T; Kimmelman J
    Mov Disord; 2021 Jan; 36(1):171-177. PubMed ID: 33002259
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterizing patient compliance over six months in remote digital trials of Parkinson's and Huntington disease.
    Cohen S; Waks Z; Elm JJ; Gordon MF; Grachev ID; Navon-Perry L; Fine S; Grossman I; Papapetropoulos S; Savola JM
    BMC Med Inform Decis Mak; 2018 Dec; 18(1):138. PubMed ID: 30572891
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
    Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
    PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.